ELEXACAFTOR/TEZECAFTOR/IVACAFTOR

Brand name:

• Trikafta®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Vertex Pharmaceuticals (Australia) Pty. Ltd.

Condition/indication:
(therapeutic use)

• Cystic fibrosis

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (–)

Comment:

--

Other PBAC consideration:

• ELEXACAFTOR + TEZACAFTOR + IVACAFTOR
• ELEXACAFTOR + TEZACAFTOR + IVACAFTOR
• ELEXACAFTOR + TEZACAFTOR + IVACAFTOR

Submission received for:

December 2021 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 10/12/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

24/01/2022

Lodgement of required documentation:

04/02/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 15/03/2022

Status:

Finalised

Government processes:

Commenced on 16/03/2022

Medicine listed on the PBS:

01/04/2022 (see PBS schedule)